Impact of early corticosteroid withdrawal on simultaneous pancreas‐kidney transplant long‐term outcomes: Single center experience and comparison to the International Pancreas Transplant Registry

Abstract

AbstractBackgroundThere remains a paucity of modern data comparing early steroid withdrawal (ESW) versus chronic corticosteroid (CCS) immunosuppression in simultaneous pancreas kidney (SPK) transplant recipients with long‐term follow‐up. Therefore, the purpose of this study is to assess the effectiveness and tolerability of ESW compared to CCS post‐SPK.MethodsThis was a retrospective single‐center matched comparison with the International Pancreas Transplant Registry (IPTR). Patients from University of Illinois Hospital (UIH) represented the ESW group and were compared to those matched CCS patients from the IPTR. Included patients were adult recipients of a primary SPK transplant between 2003 and 2018 within the US receiving rabbit anti‐thymocyte globulin induction. Patients were excluded if they had early technical failures, missing IPTR data, graft thrombosis, re‐transplant, or positive crossmatch SPK.ResultsA total of 156 patients were matched and included in the analysis. Patients were predominantly African American (46.15%) males (64.1%) with Type 1 diabetes etiology (92.31%). Overall pancreas allograft survival (hazard ratio [HR] = .89, 95% confidence interval [CI] .34–2.30, p = .81) and kidney allograft survival (HR = .80, 95%CI .32–2.03, p = .64) were similar between the two groups. Immunologic pancreas allograft loss was statistically similar at 1‐year (ESW 1.3% vs. CCS 0%, p = .16), 5‐year (ESW 1.3% vs. CCS 7.7%, p = .16), and 10‐year (ESW 11.0% vs. CCS 7.7%, p = .99). The 1‐year (ESW 2.6% vs. CCS 0%, p > .05), 5‐year (ESW 8.3% vs. CCS 7.0%, p > .05), and 10‐year (ESW 22.7% vs. CCS 9.9%, p = .2575) immunologic kidney allograft loss were also statistically similar. There was no difference in 10‐year overall patient survival (ESW 76.2% vs. CCS 65.6%, p = .63).ConclusionsNo differences were found between allograft or patient survival post‐SPK when comparing an ESW or CCS protocol. Future assessment is needed to determine differences in metabolic outcomes.